Mario Balsa: Breaking from ASCO 2025 – DESTINY-Gastric04 Trial

Mario Balsa, Medical Oncology resident at ICO, Shared a post on X:

“Breaking from ASCO25 — DESTINY-Gastric04

T-DXd outperforms RAM+PTX in 2L HER2+ advanced G/GEJ cancer:

mOS: 14.7 vs 11.4 mo (HR: 0.70, p=0.004)
mPFS: 6.7 vs 5.6 mo
cORR: 44.3% vs 29.1%
DCR: 91.9% vs 75.9%

A new standard? Eureka, you found it.”

Mario balsa